MiniMed Group (NASDAQ:MMED) Research Coverage Started at Mizuho

Mizuho began coverage on shares of MiniMed Group (NASDAQ:MMED) in a research report released on Tuesday, Marketbeat.com reports. The firm issued an outperform rating and a $21.00 price objective on the stock.

MMED has been the subject of a number of other reports. Wall Street Zen upgraded MiniMed Group to a “hold” rating in a report on Saturday, March 14th. Piper Sandler began coverage on shares of MiniMed Group in a research report on Tuesday. They set a “neutral” rating and a $16.00 target price on the stock. Bank of America began coverage on shares of MiniMed Group in a research note on Tuesday. They set a “buy” rating and a $27.00 target price for the company. Finally, BTIG Research started coverage on shares of MiniMed Group in a research report on Tuesday. They issued a “buy” rating and a $25.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.45.

MiniMed Group Stock Performance

NASDAQ MMED opened at $14.01 on Tuesday. MiniMed Group has a twelve month low of $13.52 and a twelve month high of $20.48.

MiniMed Group News Summary

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays set an “overweight” rating with a $26 price target (~85% upside vs. current price), giving a clear bullish analyst catalyst. Article Title
• Neutral Sentiment: Goldman Sachs initiated coverage on MMED (coverage note published; no widely reported price target in the release). Article Title
• Neutral Sentiment: William Blair began coverage on MMED (initial research coverage announced). Article Title
• Neutral Sentiment: Evercore initiated coverage on MMED (coverage note released). Article Title
• Neutral Sentiment: Wells Fargo initiated coverage on MMED. Article Title
• Neutral Sentiment: Piper Sandler initiated coverage on MMED. Article Title
• Neutral Sentiment: Deutsche Bank began coverage on MMED. Article Title
• Neutral Sentiment: Citigroup initiated coverage on MMED. Article Title
• Neutral Sentiment: BTIG Research initiated coverage on MMED. Article Title
• Neutral Sentiment: Mizuho began coverage on MMED. Article Title
• Neutral Sentiment: Morgan Stanley began coverage on MMED. Article Title
• Neutral Sentiment: Bank of America initiated coverage on MMED. Article Title

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.